Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06455293
PHASE2

Psilocybin Therapy for Depression in Parkinson's Disease

Sponsor: Joshua Woolley, MD, PhD

View on ClinicalTrials.gov

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Official title: The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-08-19

Completion Date

2028-06

Last Updated

2025-05-13

Healthy Volunteers

No

Interventions

DRUG

Psilocybin

Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

Locations (1)

University of California, San Francisco

San Francisco, California, United States